INTUITIVE SURGICAL INC

Discover how Intuitive Surgical’s AI‑powered robotic surgery drives ETF growth, outpaces rivals, and taps into healthcare cost‑cutting trends.

Intuitive Surgical’s July 2 gain highlights robotic‑surgery’s proven safety, faster recoveries, and cost savings—fueling investor confidence and clinical adoption.

Intuitive Surgical’s da Vinci 5 drives 11,000‑unit growth, boosting revenue, earnings and market leadership in surgical robotics.

Intuitive Surgical’s decade‑long rise: from $73 to nearly $400, a $143B market cap, high margins, R&D edge, and proven robotic‑surgery value that beats industry averages.

Intuitive Surgical’s resilient growth in a volatile tech market shows strong consumable revenue, healthy margins, and defensive positioning amid regulatory and competitive challenges.

Intuitive Surgical’s Q1 2026 stock dip is a market correction, not a business crash—analysts still see upside from growing da Vinci 5 procedure volumes, but valuation and reimbursement shifts warrant careful monitoring.

Intuitive Surgical’s analyst coverage shows steady growth amid rising competition, highlighting the da Vinci system’s innovation, market leadership, and future challenges.

Intuitive Surgical Q1 2026 earnings show strong revenue growth, expanding recurring streams, AI‑enhanced da Vinci 5 adoption and a bullish analyst outlook.

Intuitive Surgical’s Q1 earnings beat estimates, driven by da Vinci 5 sales, expanding recurring revenue and stronger margins—boosting shares and analyst optimism.

Intuitive Surgical’s Q4 2025 outlook shows 10% EPS growth and 16% revenue lift, driven by expanding da Vinci installations, consumables, and AI‑powered robotics—an indicator of continued market dominance amid rising global healthcare spend.